United Therapeutics Corporation $UTHR Stock Position Raised by Corient Private Wealth LLC

Posted by Stanley Muller on Jun 25th, 2026

Corient Private Wealth LLC grew its position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 13.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 19,248 shares of the biotechnology company’s stock after acquiring an additional 2,289 shares during the period. Corient Private Wealth LLC’s holdings in United Therapeutics were worth $9,379,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC raised its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares in the last quarter. Wellington Management Group LLP grew its position in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares in the last quarter. Finally, Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at $317,617,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on UTHR. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Bank of America raised their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Finally, HC Wainwright raised their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $619.42.

Check Out Our Latest Analysis on United Therapeutics

United Therapeutics Price Performance

NASDAQ:UTHR opened at $549.66 on Thursday. The stock has a market cap of $23.33 billion, a P/E ratio of 20.29, a PEG ratio of 1.80 and a beta of 0.57. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company has a fifty day moving average price of $562.63 and a 200 day moving average price of $525.08.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period last year, the company earned $6.63 earnings per share. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 26.49 EPS for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,540,358.40. This represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 633,718 shares of company stock worth $358,492,749 in the last 90 days. Insiders own 8.60% of the company’s stock.

About United Therapeutics

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.